Key result
Oral P2Y12 inhibitor pretreatment before PCI fails to reduce 30-day mortality in STEMI.
Why the study?
Pretreatment with oral P2Y12 inhibitors is standard practice for STEMI patients undergoing PCI, but its efficacy and safety remain unclear.
Does pretreatment with oral P2Y12 inhibitors reduce all-cause mortality, myocardial infarction, or major bleeding in STEMI patients undergoing PCI?
Population
70,465 STEMI patients across 3 randomized controlled trials and 14 observational studies
Comparison
P2Y12 inhibitor pretreatment vs no pretreatment
Design
Systematic review and meta-analysis
Follow-up
30 days
Authors
Loading...
Does not support routine pretreatment with oral P2Y12 inhibitors before PCI in STEMI; confirms no mortality benefit in this meta-analysis.
Meta-Analysis (n=70,465)
Does pretreatment with oral P2Y12 inhibitors reduce all-cause mortality, myocardial infarction, or major bleeding in STEMI patients undergoing PCI?
Relative Risk: 0.73 (95% CI 0.52–1.03)
p-value: p=0.07
Routine pretreatment with oral P2Y12 inhibitors before PCI in STEMI patients does not significantly improve 30-day mortality, MI, or major bleeding, although pre-hospital administration may reduce reinfarction.
Gewehr et al. (2023) conducted a meta-analysis in ST-elevation myocardial infarction (STEMI) (n=70,465). Oral P2Y12 inhibitor pretreatment vs. No pretreatment was evaluated on All-cause mortality at 30 days (RR 0.73, 95% CI 0.52-1.03, p=0.07). Pretreatment with oral P2Y12 inhibitors before PCI in STEMI patients did not significantly reduce 30-day all-cause mortality (RR 0.73; 95% CI 0.52-1.03; p=0.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: